Nektar Therapeutics (NKTR) Payables (2016 - 2025)
Historic Payables for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $15.6 million.
- Nektar Therapeutics' Payables rose 8145.04% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 8145.04%. This contributed to the annual value of $11.6 million for FY2024, which is 1738.42% up from last year.
- Latest data reveals that Nektar Therapeutics reported Payables of $15.6 million as of Q3 2025, which was up 8145.04% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Payables ranged from a high of $23.7 million in Q3 2021 and a low of $2.6 million during Q2 2023
- Moreover, its 5-year median value for Payables was $11.6 million (2024), whereas its average is $11.6 million.
- As far as peak fluctuations go, Nektar Therapeutics' Payables plummeted by 7878.67% in 2023, and later soared by 16085.77% in 2024.
- Over the past 5 years, Nektar Therapeutics' Payables (Quarter) stood at $9.7 million in 2021, then surged by 33.17% to $13.0 million in 2022, then decreased by 24.13% to $9.8 million in 2023, then grew by 17.38% to $11.6 million in 2024, then surged by 34.63% to $15.6 million in 2025.
- Its Payables was $15.6 million in Q3 2025, compared to $14.3 million in Q2 2025 and $17.8 million in Q1 2025.